San Francisco, April 11, 2024–(BUSINESS WIRE)– Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a company update, reporting financial results for the first quarter ended March 31, 2024 on May 2, 2024. announced that it would be reported. A conference call will be held on May 2, 2024 at 1:30 PM PT / 4:30 PM ET.
Company updates and financial results will be provided through press releases after market close and can be accessed from the press releases in the Investor section of the Vir website (www.vir.bio). Participants may access the conference call via webcast from the Events & Presentations page on Vir's website (https://investors.vir.bio/events-presentations) or by calling the U.S. toll-free number (888). You can listen by dialing 800-8770 or International+. 1 (646) 307-1953, Conference ID: 756877. A recorded version of the call will be published on the website approximately two hours after the event ends and will be archived for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on strengthening the immune system and transforming lives by treating and preventing infections and other serious conditions, including virus-related diseases. Vir has built his two technology platforms designed to utilize key observations of innate immune processes to modulate the immune system. The company's current clinical development pipeline consists of product candidates targeting hepatitis delta virus, hepatitis B virus, and human immunodeficiency virus. Vir's pipeline includes several preclinical candidates, including those targeting influenza A and B, COVID-19, RSV/MPV, and HPV. Vir regularly posts information he believes is important to investors on his website.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240411706041/ja/
contact address
media
Carly Scaduto
Senior Director, External Communications
cscaduto@vir.bio
+1 314-368-5189
Investor
Richard Lepke
Senior Director of Investor Relations
rlepke@vir.bio
+1 978-973-9986